NASDAQ:MSLE Satellos Bioscience Q2 2026 Earnings Results & Report $7.49 +0.15 (+2.04%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$7.49 0.00 (0.00%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Satellos Bioscience missed analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.56 versus the -$0.38 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeAfter Market ClosesConference Call4:00 PM ET Satellos Bioscience EPS ResultsActual EPS-$0.56Consensus EPS -$0.38Beat/MissMissed by -$0.18One Year Ago EPSN/ASatellos Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Satellos Bioscience Q2 2026 Earnings FAQ Did Satellos Bioscience beat earnings estimates for Q2 2026? Satellos Bioscience (NASDAQ:MSLE) reported earnings of -$0.56 per share for Q2 2026, missing the consensus estimate of -$0.38. The report was announced on Thursday, August 13, 2026. Satellos Bioscience Earnings HeadlinesSatellos Secures Long-Term U.S. Patent Protection for Lead Drug ForazapadinOctober 5, 2026 | tipranks.comSatellos Granted Composition of Matter Patent for ForazapadinOctober 5, 2026 | financialpost.comFFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 10 at 1:00 AM | Weiss Ratings (Ad)Satellos Bioscience Inc.: Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular DystrophyOctober 1, 2026 | finanznachrichten.deSatellos Bioscience Inc. Completes Enrollment In BASECAMP Phase 2 Clinical Trial Of Forazapadin For Duchenne Muscular DystrophySeptember 30, 2026 | marketscreener.comMSatellos Completes Enrollment In Phase 2 Forazapadin Trial For DMDSeptember 30, 2026 | rttnews.comSee More Satellos Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email. Email Address About Satellos BioscienceSatellos Bioscience (NASDAQ:MSLE) Corporation (NASDAQ:MSLE) is a biotechnology company focused on developing therapies that promote the natural regeneration and repair of skeletal muscle. Its research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and rebuilding muscle tissue after injury or disease. The company’s lead program is SAT-3247, an investigational small-molecule therapy being developed for muscle-wasting disorders, including Duchenne muscular dystrophy. Satellos is evaluating whether its approach can restore or enhance the function of muscle stem cells and improve the body’s ability to regenerate damaged muscle. Satellos Bioscience is headquartered in Canada and was established to advance research into muscle stem-cell biology and potential treatments for serious neuromuscular diseases. The company’s programs remain in development, and its therapies have not been established as safe or effective for commercial use.View Satellos Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
